AbbVie, a leading biopharmaceutical company, has taken a significant step into the obesity treatment market through a groundbreaking licensing agreement with Danish biotech firm Gubra. The deal, valued at up to $2.23 billion, marks a strategic expansion for AbbVie into a highly lucrative sector, currently dominated by industry heavyweights Novo Nordisk and Eli Lilly. With analysts predicting that the global weight-loss drug market could reach $130 billion by 2030, AbbVie’s latest move signals its intent to capture a share of this rapidly growing segment.
Details of the Licensing Agreement
The agreement grants AbbVie exclusive global rights to develop and commercialize Gubra’s experimental obesity drug,
